Pluricyte® Cardiomyocytes Validated and Optimized for Pacing using Axion BioSystems Maestro™ E-Stim+ MEA Technology

Leiden, The Netherlands, April 18th, 2017 – Pluriomics has published a new application note describing the function of electrical stimulation in Pluricyte® Cardiomyocytes by using the Maestro E-Stim+  Classic MEA™ plates in combination with the Maestro MEA system. Pluriomics’ Pluricyte® Cardiomyocytes are the first hiPSC-derived cardiomyocytes being validated and optimized for pacing using Axion BioSystems’ […]

READ MORE read more

Pluriomics expands its presence in the USA

Leiden, The Netherlands, Gosselies, Belgium, 3rd April, 2017 – Pluriomics, an emerging Belgian/Dutch biotechnology company whose mission is to deliver cardiac drug discovery and safety solutions based on its best-in-class human iPSC-derived cardiomyocyte technology, today announced that expands its USA operations to better serves its clients in North America. Pluriomics is a leading expert in human […]

READ MORE read more

News archive

Advances in Stem Cells and Regenerative Medicine

  Location: EMBL Heildeberg, Germany Date: May 23-26, 2017 Pluriomics will attend the Advances in Stem Cells and Regenerative Medicine conference at EMBL Heidelberg, Germany. This conference will provide a comprehensive overview of various aspects of stem cell biology. The cellular and molecular properties of normal tissue stem cells will be discussed, as well as […]

READ MORE read more

Industry Workshop: Advances in Cardiac Pacing

  Axion, Nanion and Pluriomics are happy to invite you to their first Industrial Workshop: “Advances in Cardiac Pacing”, which will be held on the 26th of April, 2017 at Pluriomics Headquarters, Leiden, The Netherlands. This workshop will be the first introduction to Axion E-Stim+ pacing plates which, in combination with Pluricyte® Cardiomyocytes, delivers high-quality […]

READ MORE read more

Events archive

About us

Pluriomics develops and commercializes fully functional, human iPSC-derived cardiomyocytes and provides high quality services for efficient and reliable safety pharmacology testing and cardiovascular drug efficacy screening.

Pluriomics, a leading expert in human cardiovascular stem cell technology, manufactures fully functional human iPSC derived cardiomyocytes (Pluricyte® Cardiomyocytes) using well-defined, serum-free medium that enhances the maturation and function of the cells. Pluriomics combines Pluricyte® Cardiomyocytes with innovative technologies to develop in-house cell-based assays with the objective to improve drug safety and efficacy screening.

Read more

Pluricyte® Cardiomyocyte Kit

Pluricyte® Cardiomyocyte Kit is developed and manufactured for use in drug discovery and development. The kit includes both Pluricyte® Cardiomyocytes and Pluricyte® Cardiomyocyte Medium (serum-free).

iView product information

Our solutions